A new type of ‘recreational’ drug could help people living with HIV keep their health status a secret
A new drug could treat people with HIV who live in high-risk communities by helping them to remain anonymous.
The drug, called Tivarox, is a synthetic version of the HIV virus that is used in HIV treatment, and could also help people to keep their viral load under control.
People living in high risk areas such as prisons, homeless shelters, or inner city areas are often reluctant to disclose that they have HIV because of the stigma and fear it can cause.
The drug is also illegal in most countries around the world, meaning the drug’s use in those communities remains illegal.
This is why many people in high HIV-risk environments do not seek treatment.
Instead, many people are using Tivarcox, which they claim to have taken in isolation, to avoid infection and avoid being seen as injecting drugs users.
Tivarax is a drug that uses a different mechanism to inject drugs.
It binds to the surface of the virus, which prevents it from spreading.
This means that it acts on the virus by binding to the surrounding cells, and is then delivered into the bloodstream.
This creates an extremely safe environment in which the virus cannot spread, but can still be transmitted.
Tvirus experts at the Australian Institute of Health and Welfare (AIHW) believe the drug could be an important step towards a cure for HIV.
“This is an important advance in the treatment of HIV infection, and potentially could lead to the ultimate cure,” said AIHW’s chief executive, Dr Robert Jones.
“We are working on finding new ways to make this treatment more affordable and accessible to people in Australia, and have been encouraging others to do the same.”AUSTRALIAN PHARMACY INTELLIGENCE SERVICE CEO ANDREW CHAMBERMAN said the drug had been shown to reduce the transmission of the viral load by around 95 per cent, which was comparable to other antiretroviral drugs.
“It has a remarkable ability to block the HIV-1 virus and help prevent transmission,” he said.
“There are a number of other compounds out there that we have shown to have similar effects, but these are all still experimental.”
Dr Jones said Tivarfox could be a “game changer”, because it was not currently available on the market.
“The drug has been in development for more than 10 years and is the first to have been approved in the US,” he explained.
“So it has the potential to help a large number of people, but we still need to prove it in people’s communities and to get it approved in Australia.”
Tivarfax was developed by AIDH, an Australian pharmaceutical research institute.
The company has already received more than $30 million in funding from the US government and has received a grant from the National Health and Medical Research Council (NHMRC).AIDH said it was working closely with the Australian Government to ensure that it had the necessary regulatory approvals to begin clinical trials.TIVAROX is also being tested in a pilot trial at the Queensland Institute of Technology (QIT), which is a private company that is not part of the AIHT.
Tivo Health, the pharmaceutical company which will be developing Tivarbox, will also be involved in clinical trials, which could begin as early as next year.
“We are excited about TivaroX and are committed to continuing to support its development in Australia,” said CEO and co-founder Dr Andrew Chambry.
“Tivarox is one of a small number of drugs that can help prevent new infections in people living in low- and middle-income countries, where it can be more easily available.”
The project is part of an international effort to develop a new HIV treatment called a novel anti-viral drug, which is also called a drug for prevention, according to AIH.
Tavastin, a drug developed in the UK, is the only one to date approved by the US Food and Drug Administration (FDA) for treating HIV infection.
It is currently in Phase 2 trials, but has been given the green light by the FDA to move to the full-scale clinical trials phase.
In April, AIH welcomed the FDA’s decision to approve the drug as “a significant milestone in the development of this exciting new class of HIV treatment”, and to provide “an important avenue for testing and development of new treatments”.
The drug is being tested on people who are living with chronic pain, asthma, obesity, or other chronic conditions.
Tovarcox is currently being tested by AIH on people living on the streets of Sydney.